CN108348479A - 靶向甲酰肽受体2/脂氧素a4受体(fpr2/alx)以用于治疗心脏疾病 - Google Patents

靶向甲酰肽受体2/脂氧素a4受体(fpr2/alx)以用于治疗心脏疾病 Download PDF

Info

Publication number
CN108348479A
CN108348479A CN201680068442.7A CN201680068442A CN108348479A CN 108348479 A CN108348479 A CN 108348479A CN 201680068442 A CN201680068442 A CN 201680068442A CN 108348479 A CN108348479 A CN 108348479A
Authority
CN
China
Prior art keywords
alx
fpr2
treatment
receptor
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680068442.7A
Other languages
English (en)
Chinese (zh)
Inventor
J.奥斯特罗夫斯基
R.加西亚
N.R.维尔茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN108348479A publication Critical patent/CN108348479A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680068442.7A 2015-11-24 2016-11-21 靶向甲酰肽受体2/脂氧素a4受体(fpr2/alx)以用于治疗心脏疾病 Pending CN108348479A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562259498P 2015-11-24 2015-11-24
US62/259498 2015-11-24
PCT/US2016/063036 WO2017091496A1 (en) 2015-11-24 2016-11-21 Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease

Publications (1)

Publication Number Publication Date
CN108348479A true CN108348479A (zh) 2018-07-31

Family

ID=57544530

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680068442.7A Pending CN108348479A (zh) 2015-11-24 2016-11-21 靶向甲酰肽受体2/脂氧素a4受体(fpr2/alx)以用于治疗心脏疾病

Country Status (13)

Country Link
US (1) US20180325869A1 (https=)
EP (1) EP3380091A1 (https=)
JP (1) JP2018538367A (https=)
KR (1) KR20180081528A (https=)
CN (1) CN108348479A (https=)
AU (1) AU2016359463A1 (https=)
BR (1) BR112018010155A8 (https=)
CA (1) CA3006291A1 (https=)
EA (1) EA201891007A1 (https=)
IL (1) IL259468A (https=)
MX (1) MX2018005756A (https=)
SG (1) SG11201803816RA (https=)
WO (1) WO2017091496A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6811241B2 (ja) 2015-12-10 2021-01-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト
WO2018227065A1 (en) 2017-06-09 2018-12-13 Bristol-Myers Squibb Company Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
EP3634958B1 (en) * 2017-06-09 2021-07-21 Bristol-Myers Squibb Company Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists
KR102615099B1 (ko) 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 아릴 헤테로시클릭 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
KR102615095B1 (ko) * 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 효능제
KR102803660B1 (ko) 2018-03-05 2025-05-02 브리스톨-마이어스 스큅 컴퍼니 페닐피롤리디논 포르밀 펩티드 2 수용체 효능제
CN113166134B (zh) 2018-11-26 2024-06-14 百时美施贵宝公司 作为甲酰肽2受体激动剂的吡咯烷酮衍生物
CA3185263A1 (en) 2020-07-09 2022-01-13 James A. Johnson Pyrazolone formyl peptide 2 receptor agonists
KR20230051525A (ko) 2020-08-12 2023-04-18 브리스톨-마이어스 스큅 컴퍼니 옥소피롤리딘 우레아 fpr2 효능제

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103221392A (zh) * 2010-11-17 2013-07-24 埃科特莱茵药品有限公司 桥联螺[2.4]庚酯衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101903378B (zh) * 2007-12-18 2014-03-12 埃科特莱茵药品有限公司 氨基三唑衍生物
CA2871334A1 (en) * 2012-05-16 2013-11-21 Actelion Pharmaceuticals Ltd 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
JP6811241B2 (ja) * 2015-12-10 2021-01-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト
KR102803660B1 (ko) * 2018-03-05 2025-05-02 브리스톨-마이어스 스큅 컴퍼니 페닐피롤리디논 포르밀 펩티드 2 수용체 효능제

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103221392A (zh) * 2010-11-17 2013-07-24 埃科特莱茵药品有限公司 桥联螺[2.4]庚酯衍生物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHENGXUE QIN, ET AL.: "Cardioprotective potential of annexin-A1 mimetics in myocardial infarction", 《PHARMACOLOGY & THERAPEUTICS》 *
HUAMEI FORSMAN, ET AL.: "Stable formyl peptide receptor agonists that activate the neutrophil NADPH-oxidase identified through screening of a compound library", 《BIOCHEMICAL PHARMACOLOGY》 *
JESMOND DALLI, ET AL.: "Proresolving and Tissue-Protective Actions of Annexin A1–Based Cleavage-Resistant Peptides Are Mediated by Formyl Peptide Receptor 2/Lipoxin A4 Receptor", 《THE JOURNAL OF IMMUNOLOGY》 *
MARCELO H. PETRI , ET AL.: "The role of the FPR2/ALX receptor in atherosclerosis development and plaque stability", 《CARDIOVASCULAR RESEARCH》 *
THOMAS GOBBETTI, ET AL.: "Nonredundant protective properties of FPR2/ALX in polymicrobial murine sepsis", 《PNAS》 *
VASUNDHARA KAIN, ET AL.: "Resolvin D1 activates the inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function", 《JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY》 *

Also Published As

Publication number Publication date
JP2018538367A (ja) 2018-12-27
US20180325869A1 (en) 2018-11-15
WO2017091496A1 (en) 2017-06-01
BR112018010155A8 (pt) 2019-02-26
CA3006291A1 (en) 2017-06-01
BR112018010155A2 (pt) 2018-11-21
EA201891007A1 (ru) 2018-11-30
KR20180081528A (ko) 2018-07-16
MX2018005756A (es) 2018-08-01
SG11201803816RA (en) 2018-06-28
AU2016359463A1 (en) 2018-07-12
EP3380091A1 (en) 2018-10-03
IL259468A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
CN108348479A (zh) 靶向甲酰肽受体2/脂氧素a4受体(fpr2/alx)以用于治疗心脏疾病
AU2018203357B2 (en) New methods
US10583103B2 (en) Method of treating heart failure with preserved ejection fraction with probenecid
JP2013528198A (ja) １型糖尿病の処置
JP7508496B2 (ja) 心筋症、収縮期心機能不全及びうっ血性心不全症状の治療のためのプロベネシド
Han et al. Atorvastatin may delay cardiac aging by upregulating peroxisome proliferator-activated receptors in rats
CN118453559A (zh) 炎症性疾病或骨病的预防或治疗剂及医药组合物
US20200069644A1 (en) Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure
KR102354243B1 (ko) 트롬복산-a2 수용체 길항제를 이용한 근위축증 치료 조성물 및 방법
US11524055B2 (en) Methods for treating diseases mediated by ERBB4-positive pro-inflammatory macrophages
JP6688503B2 (ja) 医薬用組成物
US20230285347A1 (en) Preterm Labour with Prostaglandin E2 Receptor Agonists
CN104220083A (zh) 用于治疗动脉硬化性血管疾病的方法和组合物
US20230114408A1 (en) Methods of modulating t-cell activation using estrogen receptor beta (erb) agonists
WO2025056188A1 (en) Relaxin medication
WO2026064493A1 (en) Inhibition of farnesyltransferase to treat cardiomyopathy and heart failure
JP2010248263A (ja) 塩酸ランジオロールを含有する頻脈性不整脈の治療剤
AU2014201695A1 (en) Therapeutic methods and compositions for treating diabetes utilizing diterpenoid compounds
CN115515580A (zh) 使用碳硼烷和碳硼烷类似物调节t细胞活化的方法
US20150265644A1 (en) Therapeutic methods and compositions for treating diabetes utilizing diterpenoid compounds
Daniels et al. Exogenous Ubiquitin Reduces Inflammatory Response and Preserves Myocardial Function 3 days Post Ischemia/Reperfusion Injury 2
HK1208363B (en) Compounds for use in the treatment of aquaporin-mediated diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180731